Not recruiting
Renal cell carcinoma
Not recruitingStudy Comparing Tivozanib and Nivolumab Combination to Tivozanib Alone in Patients with Renal Cell Carcinoma After Previous Immune Therapy
Registered drugNo placebo
Study Comparing Tivozanib and Nivolumab Combination to Tivozanib Alone in Patients with Renal Cell Carcinoma After Previous Immune Therapy
Registered drugNo placebo
- Disease:Renal cell carcinoma
- Substances:NivolumabTivozanib
Countries:
Belgium
Belgium- Participants:18–64 years · 65+ years
- Substances:Nivolumab



